Home/Imugene/Paul Hopper
PH

Paul Hopper

Executive Chairman

Imugene

Roles

Executive ChairmanatImugene
Non-Executive DirectoratIncannex Healthcare

Therapeutic Areas

Imugene Pipeline

DrugIndicationPhase
HER-Vaxx (IMU-131)HER-2/neu positive gastric & gastroesophageal junction cancerPhase 2b
CHECKvacc (CF33-hNIS-antiPDL1)Advanced or metastatic solid tumorsPhase 1
VAXINIA (CF33-hNIS)Advanced or metastatic solid tumorsPhase 1
PD1-Vaxx (IMU-201)Non-small cell lung cancer (NSCLC)Phase 1
CD19 onCARlyticsB-cell hematological malignancies (e.g., Leukemia, Lymphoma)Pre-clinical
CD20 onCARlyticsB-cell hematological malignanciesPre-clinical
BA3071Solid tumorsPre-clinical